0.75 CEUs
Core Curriculum:
Understanding Pharmacokinetics and Pharmacodynamics and Managing ART
Understanding Pharmacokinetics and Pharmacodynamics and Managing ART
Module Description
The Core Curriculum is developed out of the Academy's Fundamentals of HIV Medicine textbook and is an ideal way to learn the basics of HIV prevention, care and treatment or to gain a quick update on specific topics in HIV care. Drug-drug interactions (DDIs) are common with all classes of ARVs. Avoiding DDIs may be difficult in people who have other comorbidities or coinfections.
Credit Dates04/10/2023 – 04/09/2024
Jointly provided by Postgraduate Institute for Medicine and the American Academy of HIV Medicine.
This activity is supported by independent educational grants from Gilead Sciences and Janssen Therapeutics.
Credit Dates04/10/2023 – 04/09/2024
Jointly provided by Postgraduate Institute for Medicine and the American Academy of HIV Medicine.
This activity is supported by independent educational grants from Gilead Sciences and Janssen Therapeutics.
Learning Objectives
- Differentiate between pharmacokinetics and pharmacodynamic parameters of antiretroviral (ARV) drugs
- Appraise data regarding absorption, distribution, metabolism and excretion (ADME) of ARVs
- Understand the role of therapeutic drug monitoring in the management of select patients on ART
- Evaluate pharmacokinetic properties of ARVs and their application to constructing ART regimens
Target Audience This activity is intended for physicians, PAs, NPs, RNs, and pharmacists who engage in the care of people with HIV.
Presenter Jonathan S. Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier, Jr. MD, Education Director and Professor of Medicine
Chair Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, FL
Method of Participation and Request for Credit There are no fees for participating and receiving CME/CE credit for this activity.
During the period April 10, 2023, through April 09, 2024, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 17163. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within four weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com or visit www.pimed.com.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physician Continuing Education Credit The Postgraduate Institute for Medicine designates this internet activity for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education The Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of Accreditation Council for Pharmacy Education (Universal Activity #JA4008162-9999-23-128-H02-P). Type of Credit: Knowledge
Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours, APRN 0.5 pharmacotherapy hours.
Disclosure of Conflict of Interest Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty
Dr. Appelbaum receives consulting fees from ViiV Healthcare and Theratechnologies.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Academy managers have nothing to disclose.
Media: Internet
Computer System Requirements: This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Conflict of Interest Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty
Dr. Appelbaum receives consulting fees from ViiV Healthcare and Theratechnologies.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Academy managers have nothing to disclose.
Media: Internet
Computer System Requirements: This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
